BAY 87-2243 reduced tumor weight dose dependently (Fig. 5A) in line with a dose-dependent reduction of the mRNA expression levels of the HIF-1 target genes CA9, ANGPTL4, and EGLN3, whereas the mRNA expression levels of hypoxia-insensitive EGLN2 gene and of HIF-1α itself were not affected by compound treatment in vivo (Fig. 5B). The gene discussed is EGLN3; the disease is neoplasm.